{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:35:42Z","timestamp":1793212542743,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jaip.2026.09.021","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:04:49Z","timestamp":1790867089000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sustained Low Disease Activity During Long-Term Mepolizumab Treatment in FIP1L1::PDGFRA-Negative Hypereosinophilic Syndrome: a Multicenter Real-World Study"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7823-1827","authenticated-orcid":false,"given":"Kevin","family":"Chevalier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Barde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislas","family":"Faguer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Freymond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zakaria","family":"Lahmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Bourdin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorine","family":"Canu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"N\u00e9el","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucile","family":"Grange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Taill\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alpha Oumar","family":"Diallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divi","family":"Cornec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Belgodere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Bonnotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Chanez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Ravaiau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Trouiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Seneschal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e9lix","family":"Ackermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Marroun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Ledoult","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Rohmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Lefevre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Groh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Emmanuel","family":"Kahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2026.09.021_bib1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/all.15544","article-title":"Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes","volume":"78","author":"Valent","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2026.09.021_bib2","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13023-023-02696-4","article-title":"French guidelines for the etiological workup of eosinophilia and the management of hypereosinophilic syndromes","volume":"18","author":"Groh","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jaip.2026.09.021_bib3","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/ajh.27287","article-title":"World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management","volume":"99","author":"Shomali","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaip.2026.09.021_bib4","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jaip.2022.02.006","article-title":"An international, retrospective study of off-label biologic use in the treatment of hypereosinophilic syndromes","volume":"10","author":"Chen","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.09.021_bib5","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.mayocp.2023.02.013","article-title":"HES and EGPA","volume":"98","author":"Khoury","year":"2023","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jaip.2026.09.021_bib6","doi-asserted-by":"crossref","first-page":"5075","DOI":"10.1182\/blood-2024-194818","article-title":"Health-related quality of life, work productivity and activity impairment, and fatigue in patients with idiopathic or lymphocytic hypereosinophilic syndrome: a real-world survey","volume":"144","author":"Schwaab","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2026.09.021_bib7","article-title":"Burden of hypereosinophilic syndromes in the United States: patients\u2019 perspective","volume":"4","author":"Silver","year":"2025","journal-title":"J Allergy Clin Immunol Glob"},{"key":"10.1016\/j.jaip.2026.09.021_bib8","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/ajh.25945","article-title":"Epidemiology, clinical picture and long-term outcomes of FIP1L1-PDGFRA-positive myeloid neoplasm with eosinophilia: data from 151 patients","volume":"95","author":"Rohmer","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaip.2026.09.021_bib9","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.jaci.2009.09.022","article-title":"Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy","volume":"124","author":"Ogbogu","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.09.021_bib10","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.3390\/jcm14124309","article-title":"High disease burden and oral corticosteroid use in patients with hypereosinophilic syndrome and eosinophilic granulomatosis with polyangiitis: country-level insights into real-world management in Europe","volume":"14","author":"Hwee","year":"2025","journal-title":"JCM"},{"key":"10.1016\/j.jaip.2026.09.021_bib11","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa070812","article-title":"Treatment of patients with the hypereosinophilic syndrome with mepolizumab","volume":"358","author":"Rothenberg","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2026.09.021_bib12","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jaci.2020.08.037","article-title":"Efficacy and safety of mepolizumab in hypereosinophilic syndrome: a phase III, randomized, placebo-controlled trial","volume":"146","author":"Roufosse","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.09.021_bib13","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2026.09.021_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejim.2025.106584","article-title":"Mepolizumab improves health-related quality of life in patients with hypereosinophilic syndrome","volume":"145","author":"Roufosse","year":"2026","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jaip.2026.09.021_bib15","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1136\/annrheumdis-2015-207726","article-title":"Definition and initial validation of a lupus low disease activity state (LLDAS)","volume":"75","author":"Franklyn","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaip.2026.09.021_bib16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","article-title":"Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force","volume":"75","author":"Smolen","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaip.2026.09.021_bib17","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1136\/annrheumdis-2013-205139","article-title":"Treat-to-target in systemic lupus erythematosus: recommendations from an international task force","volume":"73","author":"Van Vollenhoven","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaip.2026.09.021_bib18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","article-title":"Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaip.2026.09.021_bib19","doi-asserted-by":"crossref","first-page":"739","DOI":"10.3899\/jrheum.2024-0502","article-title":"Low disease activity early in the course of systemic lupus erythematosus","volume":"51","author":"Ugarte-Gil","year":"2024","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaip.2026.09.021_bib20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaip.2026.09.021_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004387","article-title":"Remission versus low disease activity as treatment targets in rheumatoid arthritis: how to strike the right balance between too strict and too lenient targets? A meta-epidemiological study of individual patient data","volume":"10","author":"Duarte","year":"2024","journal-title":"RMD Open"},{"key":"10.1016\/j.jaip.2026.09.021_bib22","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaip.2026.09.021_bib23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaip.2026.09.021_bib26","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1111\/all.16463","article-title":"Hypereosinophilia and hypereosinophilic syndromes: first findings from a nationwide multicenter cohort","volume":"80","author":"Lef\u00e8vre","year":"2025","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2026.09.021_bib27","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1016\/j.jaip.2025.09.009","article-title":"Development and validation of the FIP score for the screening of FIP1L1::PDGFRA-associated hypereosinophilic syndrome","volume":"13","author":"Stammler","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.09.021_bib29","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0140-6736(09)61340-4","article-title":"Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial","volume":"374","author":"Verdecchia","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2026.09.021_bib30","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(04)16676-2","article-title":"Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial","volume":"364","author":"Grigor","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2026.09.021_bib31","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1136\/ard.2007.071092","article-title":"Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial)","volume":"66","author":"Verstappen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaip.2026.09.021_bib32","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1136\/ard-2024-225686","article-title":"Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study","volume":"83","author":"Aranow","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaip.2026.09.021_bib33","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard-2023-224624","article-title":"Benralizumab for eosinophilic granulomatosis with polyangiitis","volume":"82","author":"Cottu","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaip.2026.09.021_bib34","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa2311155","article-title":"Benralizumab versus mepolizumab for eosinophilic granulomatosis with polyangiitis","volume":"390","author":"Wechsler","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2026.09.021_bib35","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaip.2026.09.021_bib36","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/j.jaip.2018.04.033","article-title":"Long-term clinical outcomes of high-dose mepolizumab treatment for hypereosinophilic syndrome","volume":"6","author":"Kuang","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.09.021_bib37","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1093\/jleuko\/qiae152","article-title":"Hypereosinophilic syndrome response to mepolizumab in the setting of a compassionate use program","volume":"116","author":"Coussement","year":"2024","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.jaip.2026.09.021_bib38","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1016\/j.jaip.2021.07.050","article-title":"Safety and efficacy of mepolizumab in hypereosinophilic syndrome: an open-label extension study","volume":"9","author":"Gleich","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.09.021_bib39","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1038\/s41591-026-04315-8","article-title":"Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial","volume":"32","author":"Ogbogu","year":"2026","journal-title":"Nat Med"},{"key":"10.1016\/j.jaip.2026.09.021_bib40","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.jaip.2022.12.022","article-title":"Targeting IL-5\/5R for the treatment of idiopathic chronic eosinophilic pneumonia","volume":"11","author":"Delcros","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.09.021_bib41","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jaci.2023.11.002","article-title":"Mepolizumab incompletely suppresses clinical flares in a pilot study of episodic angioedema with eosinophilia","volume":"153","author":"Khoury","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.09.021_bib42","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.jaci.2024.04.033","article-title":"Beyond IL-5 inhibition for the treatment of episodic angioedema with eosinophilia (Gleich syndrome)","volume":"154","author":"Ledoult","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.09.021_bib43","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.3324\/haematol.2023.284429","article-title":"Targeting CCR4 with mogamulizumab in refractory CD3-CD4+ lymphocytic-variant hypereosinophilic syndrome","volume":"109","author":"Ledoult","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.jaip.2026.09.021_bib44","article-title":"Efficacy and safety of mepolizumab in the management of severe eosinophilic asthma: a systematic review","volume":"15","author":"Dighriri","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.jaip.2026.09.021_bib45","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/ajh.27306","article-title":"Involvement of the JAK-STAT pathway in the molecular landscape of tyrosine kinase fusion-negative hypereosinophilic syndromes: a nationwide CEREO study","volume":"99","author":"Groh","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaip.2026.09.021_bib46","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.jaip.2022.12.046","article-title":"Incidence of anti-drug antibodies to monoclonal antibodies in asthma: a systematic review and meta-analysis","volume":"11","author":"Chen","year":"2023","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221321982600810X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221321982600810X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:02:18Z","timestamp":1793210538000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221321982600810X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":43,"alternative-id":["S221321982600810X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2026.09.021","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sustained Low Disease Activity During Long-Term Mepolizumab Treatment in FIP1L1::PDGFRA-Negative Hypereosinophilic Syndrome: a Multicenter Real-World Study","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2026.09.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}